Slides
Page 1
© 2022 IMUNON, Inc. PAGE 1 IMUNON’s 2026 Investor Conference and R&D Day September 23, 2026 10:00 AM-12:00 PM EDT Sofitel, New York City
Page 2
© 2022 IMUNON, Inc. PAGE 2 Agenda Welcome - Redefining Frontline Care: Unlocking the Potential of a First-in-Class IL-12 Immunotherapy in Ovarian Cancer Stacy Lindborg, PhD President and CEO, Imunon, Inc. Resurrecting IL-12: Overcoming Historical Barriers with Targeted TheraPlas Delivery of IMNN-001 Douglas Faller, MD, PhD Chief Medical Officer, Imunon, Inc Unveiling Translational Insights: MRD Clearance, Microenvironment Remodeling, and Combination Strategies Amir Jazaeri, MD Vice Chair for Clinical Research, Director, Gynecologic Cancer Immunotherapy Program, Department of Gynecologic Oncology and Reproductive Med., University of Texas MD Anderson Cancer Center Advancing Frontline Efficacy: Translating OVATION 2 Overall Survival Signals into Pivotal Phase 3 OVATION 3 Premal H. Thaker, MD David & Lynn Mutch Distinguished Professor of Obstetrics & Gyn, Chief of Gynecologic Oncology, Director of Gynecologic Oncology Clinical Research, Professor in Gynecologic Oncology, Washington University School of Medicine Beyond the Data: Clinical Experience with IMNN-001: A Conversation with an OVATION 1 Study Participant William Bradley, MD Professor and Vice Chair for Clinical Research, Division of Gynecologic Oncology, Medical College of Wisconsin Building the Future — Strategic Milestones, Catalysts, and the Investment Horizon Stacy Lindborg, PhD President and CEO, Imunon, Inc.
Page 3
REDEFINING FRONTLINE CARE · UNLOCKING FIRST -IN -CLASS IL -12 IMMUNOTHERAPY IN OVARIAN CANCER Leave with three things. A frontline ovarian cancer program now in Phase 3. Built on randomized Phase 2 OS — and on a cytokine the field abandoned. THE PROBLEM THAT HAS NOT MOVED Newly diagnosed advanced ovarian cancer is still treated the way it has been treated for more than thirty years — platinum, taxane, surgery. The backbone saved lives. It has also plateaued. The bar that should matter is overall survival. 01 Why IL-12 failed Biology was never the problem. Systemic protein delivery was. 02 Why IMNN-001 is different Local DNA. IL-12 where the disease lives. 45.1 vs 30.4 months. No CRS in Phase 2. 03 Why OVATION 3 is the pivotal chapter Phase 2 was not powered for OS; Phase 3 is. 2 interims, Fast Track & Orphan Drug designation, FDA-aligned protocol. IMUNON 2026 R&D Day · September 23, 2026 · Opening Remarks WHERE THIS MORNING GOES 01 Faller IL-12 biology, and why TheraPlas changed the safety equation 02 Jazaeri Translational weight — MRD, ctDNA, a colder tumor turning hotter 03 Thaker OVATION 2 from the OR and clinic, and why Phase 3 cannot wait 04 Bradley and Trial Participant What the numbers mean when they are not a Kaplan-Meier curve
Page 4
Resurrecting IL-12: Overcoming Historical Barriers with Targeted TheraPlas Delivery of IMNN-001 Douglas V. Faller, MD, PhD Chief Medical Officer
Page 5
© 2022 IMUNON, Inc. PAGE 5 An immunotherapy that harnesses the patient’s own immune system; not delivering IL-12 but rather activating the immune system. A mechanism of action that activates both the innate and adaptive immune systems for a more effective, durable, and comprehensive response. IMNN-001 impacting cancer- fighting cytokines, turning the tumor environment from “Cold” to “Hot”, allowing immune system to continue to suppress the tumor for years after the completion of therapy. These cytokines are induced locally, at the site of the tumor, where they would be most active. No unwanted immune adverse events or cytokine release syndrome are seen. 5 IMNN-001: The First and Only Treatment to Demonstrate an Impact on Overall Survival in Newly Diagnosed Advanced Ovarian Cancer Potential to Transform the Frontline Standard of Care for Ovarian Cancer Patients
Page 6
© 2022 IMUNON, Inc. PAGE 6 Innate Immunity • • Acquired Immunity T lymphocytes B lymphocytes Image adapted from: Giorgio Trinchieri March 2003 Nature Reviews Immunology 3(2):133-46 • Monocytes • Macrophages • Dendritic Cells • Neutrophils • NK cells IL-12 and its Effector IFN-γ: Critical Drivers of Antitumor Immunity Harnessing Both Innate and Acquired Immunity
Page 7
© 2022 IMUNON, Inc. PAGE 7 7 IFN-γ Effects in Cancer are Multifactorial and Powerful Not Just Immune-Related but Also Affecting Pathways Regulating Cancer Progression, Angiogenesis and Apoptosis ↑IP-10 Image adapted from: Jorgovanovic D et al., . Biomark Res. 2020 Tumor dormancy
Page 8
© 2022 IMUNON, Inc. PAGE 8 IL-12 in Cancer Immunotherapy is Biologically Powerful The Challenge has Been to Harness it Locally 1989–93 IL-12 discovered; potent antitumor activity in mice 1995–97 1997–2014 2020–23 2021 2025 Systemic rIL-12: cytokine storm, 2 deaths; US trials halted 38 systemic trials; no meaningful benefit (DLTs blocked dose escalation) OVATION-1: IMNN-001 + chemo with encouraging clinical responses Local delivery programs (Tavo, MEDI1191) miss primary endpoints OVATION-2 OS signal; OVATION-3 Phase 3 underway
Page 9
© 2022 IMUNON, Inc. PAGE 9 IMNN-001 Superior Positioning Relative to Other IL-12 Delivery Strategies Shared Goal: Maximize Tumor-Local IL-12 While Limiting Systemic Exposure Evolving IL-12 Platforms ● Intratumoral mRNA/LNP systems drive local cytokine expression ● Targeted immunocytokines and anchored proteins improve tumor retention ● Viral vectors, EVs, and engineered cells add options but stay platform-specific Key Translational Challenges ● Systemic recombinant IL-12: poor pharmacokinetics and a narrow therapeutic index ● Intratumoral injection needs accessible lesions and misses disseminated disease ● Off-target expression, repeat-dose tolerability, and manufacturing remain constraints IMNN-001 Positioning ● Regional IP delivery matches peritoneal spread in ovarian cancer ● Non-viral plasmid enables local expression and repeat dosing ● Covers the peritoneal compartment without injecting individual lesions IMNN-001 is a regional, repeatable, non-viral IL-12 approach for peritoneal ovarian cancer—local delivery, systemic antitumor activity. IMNN-001 is the only program currently in late clinical trials with evidence of a Survival Effect © 2026 IMUNON, Inc.
Page 10
© 2022 IMUNON, Inc. PAGE 10 IMNN-001 Local Expression of IL-12 Favors Immune Modulation in Tumor Microenvironment Intraperitoneal IMNN-001 produces durable, local IL-12 in the peritoneum. Avoids the supraphysiologic IL-12 spikes of bolus IV rIL-12, limiting systemic exposure and supporting a favorable safety profile. IMNN-001: Local IL-12 Production in the Tumor Microenvironment Durable Peritoneal Expression Without Bolus-Like Systemic IL-12 Spikes
Page 11
© 2022 IMUNON, Inc. PAGE 11 TheraPlas combines a therapeutic gene plasmid and proprietary delivery system into nanoparticles to achieve durable local production of a therapeutic protein after in vivo administration at the disease site Nanoparticles IMNN-001 Therapeutic Plasmid System Plasmid Delivery System Gene Expression Vector TheraPlas Synthetic DNA Delivery Systems Expresses Therapeutic Gene(s) ▪ Immune agents (cytokines, chemokines) ▪ Anti-cancer agents ▪ Growth factors Polymeric Systems ▪ Lipopolymers ▪ Cross-linked polymers Local & Systemic Delivery Therapeutic Protein Broad Product Opportunities Across Molecular Targets, Delivery Modalities, and Disease Area TheraPlasTM: Local, Durable Protein for Repeated Administration
Page 12
© 2022 IMUNON, Inc. PAGE 12 IP IMNN-001 in Advanced Epithelial Ovarian Cancer: Localized Delivery for Diffuse Disease Designed to Convert a Cold Peritoneal TME to a Hot Antitumor TME IFN- activates anti-tumor TME response IFN- inhibits immune suppressive TME
Page 13
© 2022 IMUNON, Inc. PAGE 13 OVATION-2OVATION-1 Marked Dose-Dependent Increase in Anti-Cancer Cytokine Levels at the tumor site IMNN-001 creates a “hot” anti-tumor microenvironment in EOC by: ▪ Increasing the recruitment of CD8+, myeloid dendritic cells and M1 macrophages in 50- 80% of the paired samples in tumor and stroma; ▪ Decreasing immunosuppressive markers (IDO, Treg, exhausted CD8, M2 macrophages) in 65-80% of the tumor and stroma samples. The induction of favorable ratios of CD8+/Tregs and CD8+/CD4+ cells, is historically associated with improved patient outcomes IMNN-001: Biomarker Data Consistent with TME Remodeling in Ph1 and Ph2 Studies Immune Biomarkers Measured in Clinical Samples Confirm IMNN-001 Mechanism of Action OVATION-2 Anwer K et al., . SITC 2025
Page 14
© 2022 IMUNON, Inc. PAGE 14 OVATION-2 Safety: Demonstrating the Successful Overcoming of Historical IL-12 Barriers Subjects with at Least One, n (%) Control arm (N/ACT) n=58 Experimental arm (IMNN-001 + N/ACT) N=59 TEAEs 56 (96.6) 59 (100) STEAEs 21 (36.2) 43 (72.9) TEAEs of special interest 16 (27.6) 39 (66.1) Abdominal Pain 16 (27.6) 39 (66.1) Cytokine Release Syndrome . . TEAEs leading to IMNN-001 dose reduction*# NA 9 (15.2) Abdominal Pain NA 7 (11.9) Others (deconditioning) NA 1 (1.7) each TEAE Leading to Study Drug D/C NA 14 (23.7) Abdominal pain NA 2 (3.4) Respiratory failure NA 2 (3.4) Others (n=8) NA 1 (1.7) each TEAE Leading to death 1 (1.7) 1 (1.7) Pancytopenia . 1& (1.7) Upper GI hemorrhage 1 (1.7) . Respiratory failure . 1& (1.7) Serious TEAEs (IMNN-001 or N/ACT related) with incidence >10% in the experimental arm Total Grades1&2 Grade 3 Grade 4 Thrombocytopenia 9 (15.3) 1 (1.7) 4 (6.8) 4 (6.8) Nausea 7 (11.9) 3 (5.1) 5 (8.5) . Abdominal pain 8 (13.6) . 8 (13.6) . Febrile neutropenia 7 (11.9) . 7 (11.9) . Anemia 7 (11.9) . 7 (11.9) . Vomiting 6 (10.2) 1 (1.7) 5 (8.5) . Pyrexia 6 (10.2) 5 (8.5) 1 (1.7) . (Safety Population) TEAE: Treatment Emergent Adverse Event; STEAE: Serious TEAE. (*) Dose reduction for IMNN-001 was 80 mg/m2 from the intended 100 mg/m2 (#) 2 additional patients had dose reductions due to port issues.(&) Occurring in the same patient. ▪ Most TEAEs and Serious TEAEs related to treatment were gastrointestinal and cytopenias ▪ TEAEs of special interest were abdominal pain (66% in experimental vs 28% in control), and cytokine release syndrome with no reported events ▪ Abdominal pain was the most common cause of IMNN-001 dose reduction (12% of patients but only 3% discontinued treatment) ▪ No serious systemic toxicity or immune-related events reported ▪ 1 pt died in each arm, unrelated to IMNN-001 IMNN-001 Allows Safe and Tolerable Repeated Delivery of Tumor-Localized IL-12
Page 15
© 2022 IMUNON, Inc. PAGE 15 IMNN-001 Consistent Safety Profile: OVATION-2, OVATION-3 and MRD Trial Safety ▪ No cytokine release syndrome ▪ No serious systemic toxicity ▪ No immune-related adverse events ▪ Consistent safety profile observed across multiple studies – Imunon has overcome the historical safety and efficacy barriers associated with the development of a novel IL-12 immunotherapy ▪ Most TEAEs related to treatment are gastrointestinal ▪ IDMC for OVATION-3 (MAY2026) - No safety concerns – continue trial without modification ▪ IDMC for MRD Study (AUG2026) - No safety concerns – continue trial without modification IMNN-001 Continues to Allow Safe and Tolerable Repeated Delivery of Tumor-Localized IL-12
Page 16
© 2022 IMUNON, Inc. PAGE 16 IMNN-001: Defining the Modern Era of IL-12 in Cancer Immunotherapy Flexible and scalable manufacturing Reliable expression of IL-12 Stability of drug product at 4°C Limited systemic exposure Induction of immune response Direct access to the TME IMNN-001 potential in other cancers · gastric, pancreatic, colorectal, glioblastoma, mesothelioma
Page 17
© 2022 IMUNON, Inc. PAGE 17 IMNN-001 Current and Potential Future Indications Platform Delivery Program Indication(s) Discovery IND enabling Phase 1 Phase 2 Phase 3 TheraPlas IP IL-12 (OVATION 3) Newly Diagnosed Adv. Ovarian Cancer IL-12 in combination with Avastin* Newly Diagnosed Adv. Ovarian Cancer IL-12 (OVATION 2) Newly Diagnosed Adv. Ovarian Cancer IL-12 in combination with Immune checkpoint Inhibitors Newly Diagnosed Adv. Ovarian Cancer IL-12 Colorectal Cancer IL-12 Pancreatic Cancer Intra- tumoral IL-12 Glioblastoma IMNN-001 enrolling IMNN-001 enrolling IMNN-001 complete IMNN-001 IMNN-001 IMNN-001 IMNN-001 Ready Ready Ready Platform Capable of a Pipeline of DNA-Based Transformative Medicines
Page 18
© 2024 IMUNON, Inc. PAGE 18 Thank you
Page 19
Phase II Randomized Translation Study of Clinical and Biological Changes Induced by IMNN-001 (MRD) Phase in Advanced Stage High Grade Serous Ovarian Cancer Amir Jazaeri, MD Professor and David Gershenson Chair in Ovarian Cancer Research Vice Chair for Clinical Research Director of Gynecologic Cancer Immunotherapy Program Department of Gynecologic Oncology & Reproductive Medicine University of Texas MD Anderson Cancer Center
Page 20
20R A D I C A L C O L L A B O R A T I O N MRD* Study Rationale • Frontline therapy offers the best opportunity to achieve cure for ovarian cancer. • IL-12 boost adaptative immunity in “cold” tumors. Systemic IL-12 is poorly tolerated; intraperitoneal delivery has a favorable safety profile. • Combining IL-12 with chemotherapy has been shown to improve frontline treatment • Better understanding of mechanisms of action will be fundamental for future development MRD: Measurable Residual Disease
Page 21
21R A D I C A L C O L L A B O R A T I O N Suspected Stage III/IV OVCA patients recommended to receive neoadjuvant chemotherapy NACT+BEV+IMNN-001 for 4 cycles NACT+BEV for 4 cycles Interval Cytoreductive Surgery ACT+BEV+IMNN-001 for 3 cycles ACT+BEV for 3 cycles MRD Detection by SLL HRD: BEV+Olaparib HRP: BEV+IMNN-001 Frontline Therapy Maintenance Therapy Serial analysis of tumor tissue, cfDNA, microbiome and i.p. fluid (experimental arm only) Experimental Arm Control Arm HRD: BEV+Olaparib HRP: BEV Diagnostic Laparoscopy IP Port Placement Screening Primary Endpoint: MRD+ rate at SLL Secondary Endpoint: PFS R
Page 22
22R A D I C A L C O L L A B O R A T I O N Clinical Data Updates
Page 23
23R A D I C A L C O L L A B O R A T I O N Clinical and Demographic Data for ITT Cohort Characteristic Overall N = 261 Control N = 121 Exp N = 141 p-value Age at randomization, years 66.5 (62.0, 72.0) 68.5 (61.5, 72.0) 65.0 (62.0, 71.0) 0.5 Race 0.2 Asian 1 (3.8%) 1 (8.3%) 0 (0%) Other 1 (3.8%) 1 (8.3%) 0 (0%) White 24 (92%) 10 (83%) 14 (100%) Ethnicity 0.085 Hispanic 2 (7.7%) 2 (17%) 0 (0%) Non-Hispanic 23 (88%) 9 (75%) 14 (100%) Not Hispanic 1 (3.8%) 1 (8.3%) 0 (0%) HRD status 0.9 HRD neg 13 (50%) 7 (58%) 6 (43%) HRD pos 8 (31%) 3 (25%) 5 (36%) BRCA 2 1 1 Unknown 5 (19%) 2 (17%) 3 (21%) 1Median (Q1, Q3); n (%)
Page 24
24R A D I C A L C O L L A B O R A T I O N Treatment Course and SLL Outcome for ITT Cohort MRD positive rate in control arm (lower is better): 66.7% (6/9) MRD positive rate in experimental arm: 44.4% (4/9) ctDNA clearance rate in control arm (higher is better): 62.5% (5/8*), ctDNA clearance rate in experimental arm: 87.5% (7/8*) *1 participant in each arm without ctDNA collection
Page 25
25R A D I C A L C O L L A B O R A T I O N Clinical Characteristics (Evaluable Patients) Characteristic Overall Control Experimental p-valueN = 181 N = 91 N = 91 Time to ICS, months 3.5 (3.1, 4.4) 3.3 (3.1, 4.1) 3.7 (3.2, 4.4) 0.14 CRS 0.5 1 2 (12%) 2 (25%) 0 (0%) 2 10 (59%) 4 (50%) 6 (67%) 3 5 (29%) 2 (25%) 3 (33%) Not yet available 1 1 0 Residual disease at ICS 0.3 R0 10 (63%) 6 (75%) 4 (50%) R1 5 (31%) 1 (13%) 4 (50%) R2 1 (6.3%) 1 (13%) 0 (0%) Not yet available 2 1 1 Time to SLL, months 8.1 (7.0, 9.2) 7.8 (7.0, 8.7) 8.2 (7.3, 9.2) 0.2 SLL positivity 10 (56%) 6 (67%) 4 (44%) 0.6 Reached NED after frontline therapy 14 (78%) 5 (56%) 9 (100%) 0.082 1n (%), Median (Min, Max) CRS: Chemotherapy Response Score NED: No evidence of Disease
Page 26
26R A D I C A L C O L L A B O R A T I O N Recurrence-Free Survival: Median Twice as Long in the Experimental Arm ITT population
Page 27
27R A D I C A L C O L L A B O R A T I O N Translational Data Updates
Page 28
28R A D I C A L C O L L A B O R A T I O N Imunon Translational Study Design and Sample Collection S = sample P = patient
Page 29
29R A D I C A L C O L L A B O R A T I O N Integrating all Samples (Visium HD Data)
Page 30
30R A D I C A L C O L L A B O R A T I O N Integrating all Samples (Visium HD Data) Fib_OGN Fib_STAR
Page 31
31R A D I C A L C O L L A B O R A T I O N Proportion Among TME Cells Over Time (Visium HD Data)
Page 32
32R A D I C A L C O L L A B O R A T I O N IL-12 expression in macrophages IL-12 expression in iCAF IL-12A IL-12B IL-12A IL-12B
Page 33
33R A D I C A L C O L L A B O R A T I O N Spatial Map of Samples (Interval Surgery - Exp Arm)
Page 34
34R A D I C A L C O L L A B O R A T I O N IL-12A/B Density
Page 35
35R A D I C A L C O L L A B O R A T I O N IL-12-Positive Spatial Field Across Control, Experimental Arm Samples p.adj = 0.0016 p.adj = 0.0004 Clinical Group
Page 36
36R A D I C A L C O L L A B O R A T I O N Spatial and Phenotypic Features of IL-12-Positive Spatial Field Fib_STAR
Page 37
37R A D I C A L C O L L A B O R A T I O N Longitudinal Changes of TCR Clones (scTCR-seq Data) Top 15 clone FC (baseline -> peak) Exp MRD- Exp MRD+ Ctl MRD- Ctl MRD+ Log2FC (baseline -> peak)
Page 38
38R A D I C A L C O L L A B O R A T I O N Summary • While preliminary, our data demonstrate lower MRD positive rates and higher CRS, lower NED positive rates, and PFS in the chemo + IMNN-001 arm • IMNN-001 treatment may drive the expansion of macrophages, with a concurrent reduction of myeloid cancer associated fibroblast (myCAF) • Macrophages are the major cell population that express IL-12 upon treatment, also lower levels of expression in inflammatory cancer associated fibroblasts (iCAFs). • IMNN-001 treatment drives TCR clonal expansion suggesting induction of anti- cancer immunity MRD: Measurable Residual Disease CRS: Chemotherapy Response Score NED: No evidence of Disease (lower is better)
Page 39
39R A D I C A L C O L L A B O R A T I O N Future Directions • Complete enrollment on the MRD Study and first abstract in 2027 • Integration of transcriptomics (RNA) with CODEX (protein) data to better understand the IL-12+ spatial field • Integration with genomic data to understand tumor clonal evolution and the TME of tumor clones • Analysis of serial gut microbiome samples collected from patients in both arms and correlation with efficacy.
Page 40
Premal H. Thaker, MD David & Lynn Mutch Distinguished Professor of Obstetrics & Gyn, Chief of Gynecologic Oncology, Director of Gynecologic Oncology Clinical Research, Professor in Gynecologic Oncology Washington University School of Medicine Advancing Frontline Efficacy: Translating OVATION 2 Overall Survival Signals into Pivotal Phase 3 OVATION 3
Page 41
Ovarian Cancer: One of the Deadliest Gynecologic Malignancies Despite decades of research, current treatments remain insufficient to change that. No improvement in survival from front-line therapies for more than 25 years. 12,450 U.S. deaths estimated in 2026 51.6% 5-year relative survival rate ~80% of advanced-stage patients relapse after initial chemotherapy 5-Year Survival Sharply Diverges by Stage at Diagnosis Localized — 20% of cases 91.7% Distant/metastatic — 80% of cases 31.8% Source: American Cancer Society, CDC, NCI SEER, NIH/PMC
Page 42
Disease Burden Ovarian cancer is often discovered late. Therefore, many women have extensive disease at diagnosis. Recurrence is common. The later ovarian cancer is detected, the harder it is to achieve long-term disease control. Treatment Burden Recurrence Burden Treatment can be physically demanding (major abdominal surgery and chemo); cancer can become resistant to chemo Desperately need treatment that extends life. No other frontline trial has shown an improvement in overall survival. Ovarian Cancer Current State: Difficult to Detect. Difficult to Control.
Page 43
R 1:1 SoC N/ACT alone (control arm) IMNN-001+N/ACT (experimental arm) OVATION-2 Study Schema A Frontline Blueprint: Immunotherapy Inside the Standard Perioperative Path Thaker et al.,Gynecol Oncol, 2025 • Localized IL-12, Systemic Safety • Demonstrated change in the tumor microenvironment • Early treatment regimen (with neoadjuvant chemo) – Best positioned to support complete cytoreduction surgery (R0) – the strongest predictor of overall survival • Activating anti-tumor immunity asap • Durable effect • At second look, less MRD and more ctDNA clearance • Macrophages in the peritoneum taking up IMNN-001 and producing IL-12 locally What Phase 2, OVATION 2 and MRD, has Taught Us
Page 44
© 2022 IMUNON, Inc. PAGE 44 OVATION 2 Data Show Continued IMNN-001 OS Improvement PARPi maintenance treated population: July 2024 Δ medians NE→ FINAL Analysis: Dec 2025 Δ medians 24.2 months Treatment window ITT, all-comers population: July 2024 Δ medians 11.1 months → FINAL Analysis: Dec 2025 Δ medians 14.7 months From clinically meaningful to transformational frontline treatment potential
Page 45
OVATION-2 Biomarker Research Confirms Local Immune Activation at the Tumor Site IMNN-001 creates a “hot” anti-tumor microenvironment in EOC Anwer et al.,SITC, 2025 CD8+ T-cells Myeloid dendritic cells M1 macrophages Anti-tumoral cells Immunosupp- ressive cells Treg-cells MDSC - M2 macrophages HOT COLD
Page 46
OVATION-2: A Consistency of Evidence All Primary and Secondary Endpoints, and Safety Profile, Favor IMNN-001 Given the positive effect across a variety of subgroups and endpoints And the biologic effects of the mechanism of action A positive safety profile (no cytokine release, systemic toxicity or immune events) IMNN-001 is showing us consistent signals that this could provide women a meaningful extension and quality of life. Ref: Thaker et al. 2025 Gyn Onc
Page 47
OVATION 2 Data: Why is This Important? What the Doctor Sees and What the Patient FeelsPhysician Perspective • Clinical win for the sickest patients:those starting NACT, not a selected PARPi- maintenance population. • Translational proof the tumor microenvironment actually changes — innate and adaptive immunity enabling both to be engaged. • Durable progression-free and overall survival benefit in ALL patients, with the strongest benefit in BRCA/HRD patients. Patient Perspective • Hope after decades of little progress: more than a year of additional life — time with family, work, and meaningful milestones that patients measure. • Treatment is time-limited (peri-operative IP course), not 2–3 years of daily PARPi or 15 months of bevacizumab. • Quality of extra time, not just quantity — localized delivery, manageable side effects, short treatment window.
Page 48
Case Study
Page 49
• Patient: 45-year-old, female • Diagnosis: Stage IV, high grade serous carcinoma, BRCA/HRD • Tumor present in ovary, peritoneum, omentum, ascites and in hiatal hernia extending in chest cavity • Treatment: • 6 doses of carboplatin and paclitaxel (3 NACT & 3 adjuvant) • 15 weekly doses of IMNN-001 (88% dose intensity, 8 NACT & 9 adjuvant setting) • PARPi in maintenance (olaparib given for 29 mo) • Anti-Tumor Activity at IDS: R2 resection & Chemotherapy Response Score of 2; ORR PR -> CR and maintained for 2 years • Serological Response: CA125 = 1464 at diagnosis, normalized by C4 • IMNN-001 Related AEs: • Grade 3 hematologic toxicities (anemia, leukopenia, neutropenia, thrombocytopenia) possibly related to IMNN-001 and chemotherapy. • Grade 1 gastrointestinal AEs (abdominal pain, diarrhea, nausea, vomiting) • SAE possibly related to IMNN-001: fever Progression at 34 months Deceased at 70 months IMNN-001 in Combination with N/ACT Demonstrated a Deep and Durable Response in a Patient with Stage IV, High Grade Carcinoma, BRCA Mutant and HRD
Page 50
OVATION-3 Pivotal Phase 3 Study A Randomized Phase III Trial Evaluating the Safety and Efficacy of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Standard Neoadjuvant and Adjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Page 51
OVATION-3: Purposeful Protocol Design and Rigorous Methodology Leveraging OVATION-2 Signals and Structure • Well controlled study with treatment and control arms, and protocol-specified maintenance • Stratification for added confidence, balance across treatment arms with Stage at diagnosis • Clinically meaningful Primary Endpoint Overall Survival • Secondary endpoints that further evidence efficacy, safety and patient perspectives/Quality of Life • Event driven statistical methodology with interim analyses designed for early submission for full approval • Consistent prophylactic pain regimen - improved mgmt. of abdomen pain/discomfort with infusions Frontline Therapy Maintenance Therapy Diagnostic Laparoscopy R (1:1) NACT (3 cycles) + IMNN-001 (weekly) NACT (3 cycles) Interval Debulking Surgery ACT (3 cycles) + IMNN-001 (weekly) ACT (3 cycles) EOT visit PARPi treatment: HRD participants only PARPi treatment: HRD participants only N=500 Stage IIIB/C or IV EOC patients recommended to received NACT
Page 52
OVATION-3: Study Momentum Motivated by Phase 2 Results Strong Progress Demonstrates Confidence • Advanced from protocol submission to site activation in approximately 6 months • Protocol approval to first patient randomized in approximately 2 months, a third of the time of the external industry benchmark. • Rapid site activation and enrollment exceeding forecast • Study level enrollment of 0.5 patients/site/month (vs typically lower industry level of 0.3 and observed rate of 0.2 from OVATION-2) • Enrollment completion targeted for Q1 2029 • Highly promising clinical and biomarker data driving strong enthusiasm • Two pre-planned interim analyses planned to support regulatory submissions as early as possible
Page 53
If Replicated in Phase 3, IMNN-001 Will Be Included in Global Standard of Care IMNN-001 results provide great hope due to: • Mechanism of Action with IL-12, and IFN- downstream effector cytokine, well documented to exert profound anti-tumor activity • Delivery to the tumor microenvironment induces potent immune responses, and avoids IL-12 mediated systemic toxicities • IMNN-001 is engineered to safely allow for repeated dosing over an extended period, making it an ideal therapeutic to continuously recruit the immune system in its fight against the malignancy • Across many trials, the safety profile has been consistent and tolerable • Clinical benefit in overall survival unseen in any other front-line ovarian cancer trial • Consistency of clinical endpoints demonstrates early antitumor effects in addition to long-term effects, prolonging life • If results are replicated in Phase 3, IMNN-001 would be the first advancement in >25 years for front-line treatment of ovarian cancer. This would change the standard of care.
Page 54
IMNN-001: From Fighting Ovarian Cancer to Changing its Trajectory Targeting ovarian cancer where it starts Frontline Immunity Localized Intentional 54 Delay relapse, Extend survival Change the trajectory before recurrence defines it. Ultimately transform ovarian cancer treatment outlooks Women diagnosed tomorrow should not inherit yesterday’s ceiling.
Page 55
Thank you
Page 56
I M U N O N R & D D A Y 2 0 2 6 V I D E O I N T E R V I E W Beyond the Data Clinical Experience with IMNN-001 A Conversation with an OVATION 1 Study Participant W I T H William Bradley, MD Professor and Vice Chair for Clinical Research Division of Gynecologic Oncology Medical College of Wisconsin PLAY VIDEO INTERVIEW A firsthand account of treatment with IMNN-001 and life in the years following the study. William Bradley, MD Investigator · OVATION Program IMNN-001 is an investigational therapy and has not been approved by the FDA. September 23, 2026 · New York
Page 57
B UI L DIN G T HE FUT UR E · ST R A T E G I C MI L E ST ON E S, C A T A L Y ST S, A N D T HE I N VE ST ME N T HOR I Z ON Confirm the Signal. First-in-class locally delivered IL-12. A randomized overall-survival signal the field has not seen. A Phase 3 already underway. OVATION 2 · ITT +14.7 mo Median OS 45.1 vs 30.4 PARP MAINTENANCE +24.2 mo Median OS 65.6 vs 41.4 HISTORICAL BARRIER 0 CRS No cytokine-release syndrome in Ph2 OVATION 3 PACE ~0.5 Pts / site / mo vs 0.3 planned 01 The thesis Local IL-12. Randomized ~15-month OS signal. A potential new standard — if Phase 3 confirms. 02 The Phase 3 clock OS primary. Two interims. DMC: continue. Enrollment ahead. Target full enrollment Q1 2029. 03 What we are asking Enroll the right patients, Deliver high-quality data. Diligence the data, Assess investment opportunity. THE LINE WE ARE HOLDING A 15-month median overall-survival difference in Phase 2 is not a press release. It is more time to be mothers and daughters. More holidays, birthdays and time making memories. Phase 2 was not powered for OS. Capital is required to fund the study to a confident decision point. Confirming the signal from Phase 2 is the work. IMUNON 2026 R&D Day · September 23, 2026 · Closing Remarks
Page 58
I M U N O N 2 0 2 6 R & D D A Y NASDAQ: IMNN L I V E D I S C U S S I O N Questions & Discussion We welcome questions from those joining us in New York and via webcast. IN THE ROOM Please raise your hand. A microphone will be brought to you. ON THE WEBCAST Submit questions through the webcast console at any time. AFTER THE EVENT Follow-up inquiries: InvestorRelations@imunon.com Sofitel New York · September 23, 2026 www.imunon.com
Page 59
© 2022 IMUNON, Inc. PAGE 59 IMUNON’s 2026 Investor Conference and R&D Day September 23, 2026 Sofitel, New York City